文献速递淋巴瘤造血干细胞移植与细胞治疗

33例间变大细胞淋巴瘤造血干细胞移植后结局分析

[Outcomes of 33 patients with anaplastic large cell lymphoma treated after hematopoietic stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该回顾性研究纳入33例接受造血干细胞移植的ALCL患者,auto-HSCT组25例、allo-HSCT组8例。两组生存曲线差异无统计学意义(OS P=0.247,PFS P=0.317)。auto-HSCT组2年OS率72%、5年OS率36%;allo-HSCT组分别为50%和25%。

要点

  • auto-HSCT后中位PFS和OS均为15个月。
  • allo-HSCT组移植相关死亡率为37.5%,auto-HSCT组为8.0%。
  • 有不良预后因素者化疗后序贯auto-HSCT为重要治疗措施。

核心结论

  • ALCL化疗反应率高,有不良预后因素时化疗后序贯auto-HSCT为重要治疗措施。
  • 高危患者或可从allo-HSCT中获益。

研究设计与样本

  • 回顾性分析全国八家三甲医院2005年1月至2017年12月收治的33例接受HSCT的ALCL患者临床资料。
  • 25例接受auto-HSCT(ALK(+)19例,ALK(-)6例),8例接受allo-HSCT(ALK(+)5例,ALK(-)3例)。
  • 移植后中位随访时间18.7(4.0~150.0)个月。

主要发现

  • 33例患者中位发病年龄31(12~57)岁,男23例、女10例。
  • ALK(+)24例(72.7%),ALK(-)9例(27.3%)。
  • 移植前完全缓解6例(均行auto-HSCT),部分缓解16例(auto-HSCT组14例、allo-HSCT组2例),复发难治11例(auto-HSCT组5例、allo-HSCT组6例)。
  • 疾病进展死亡7例,auto-HSCT组5例(20.0%),allo-HSCT组2例(25.0%)。
  • 移植相关死亡5例,auto-HSCT组2例(8.0%),allo-HSCT组3例(37.5%)。

关键数值与推荐

  • auto-HSCT后中位PFS和OS均为15个月。
  • allo-HSCT后中位PFS为3.7(1.0~90.0)个月,中位OS为4.6(1.0~90.0)个月。
  • 两组生存曲线差异无统计学意义(OS P=0.247,PFS P=0.317)。
  • auto-HSCT和allo-HSCT组2年OS率分别为72%和50%,5年OS率分别为36%和25%。

临床怎么用

  • 有不良预后因素的ALCL患者,化疗后序贯auto-HSCT为重要治疗措施。
  • 高危ALCL患者可考虑allo-HSCT,但需注意其较高的移植相关死亡风险。

局限性

  • 回顾性研究,样本量较小(33例),allo-HSCT组仅8例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the efficacy and prognostic factors of hematopoietic stem cell transplantation (HSCT) for the treatment of patients with anaplastic large cell lymphoma (ALCL) . Methods: The clinical records of 33 ALCL patients after HSCT were collected and analyzed retrospectively to evaluate the rates of overall survival (OS) and recurrence after autologous (auto-HSCT) and allogeneic HSCT (allo-HSCT) and the factors influencing prognosis. Results: The median-age of this cohort of 33 ALCL cases at diagnosis was 31 (12-57) years old with a male/female ratio of 23/10, 24 cases (72.7%) were ALK(+) and 9 ones (27.3%) ALK(-). Of them, 25 patients (19 ALK(+) and 6 ALK(-)) underwent auto-HSCT and 8 cases (5 ALK(+) and 3ALK(-)) allo-HSCT with a median follow-up of 18.7 (4.0-150.0) months. Disease states before HSCT were as follows: only 6 patients achieved CR status and received auto-HSCT, 16 patients achieved PR (14 cases by auto-HSCT and 2 ones allo-HSCT) , the rest 11 cases were refractory/relapse (5 cases by auto-HSCT and 6 ones allo-HSCT) . There were 7 cases died of disease progression (5 after auto-HSCT and 2 allo-HSCT) and 5 cases treatment-related mortality (TRM) (2 after auto-HSCT and 3 allo-HSCT) , TRM of two groups were 8.0% and 37.5%, respectively. Both the median progression-free survival (PFS) and OS were 15 months after auto-HSCT, the median PFS and OS after allo-HSCT were 3.7 (1.0-90.0) and 4.6 (1.0-90.0) months, respectively. There was no statistically significant difference in terms of survival curves between the two groups (OS and PFS, P=0.247 and P=0.317) . The 2-year OS rates in auto-HSCT and allo-HSCT groups were 72% and 50%, respectively. The 5-year OS rates in auto-HSCT and allo-HSCT groups were 36% and 25%, respectively. Conclusion: ALCL treated by chemotherapy produced high rates of overall and complete responses. Chemotherapy followed by auto-HSCT remained to be good choice for patients with poor prognostic factors. High-risk patients should be considered more beneficial from allo-HSCT. 目的: 探讨造血干细胞移植治疗间变大细胞淋巴瘤(ALCL)的疗效及预后。 方法: 回顾性分析全国八家三甲医院2005年1月至2017年12月收治的33例接受造血干细胞移植(HSCT)的ALCL患者临床资料,评价自体造血干细胞移植(auto-HSCT)和异基因造血干细胞移植(allo-HSCT)治疗ALCL的生存率、复发率和影响预后的相关因素。 结果: 33例接受HSCT的ALCL患者的中位发病年龄为31(12~57)岁,男23例,女10例,间变性淋巴瘤激酶阳性(ALK(+))和阴性(ALK(-))分别为24例(72.7%)和9例(27.3%)。25例患者接受auto-HSCT(ALK(+)患者19例,ALK(-)患者6例),8例患者接受allo-HSCT(ALK(+)患者5例,ALK(-)患者3例)。移植后中位随访时间18.7(4.0~150.0)个月。移植前疾病缓解状态:完全缓解6例(均行auto-HSCT),部分缓解16例(auto-HSCT组14例,allo-HSCT组2例),复发难治11例(auto-HSCT组5例,allo-HSCT组6例)。疾病进展死亡7例,其中auto-HSCT组5例(20.0%),allo-HSCT组2例(25.0%)。移植相关死亡(TRM)5例,其中auto-HSCT组2例(8.0%),allo-HSCT组3例(37.5%)。auto-HSCT后中位无进展生存(PFS)和总生存(OS)时间均为15个月,allo-HSCT后中位PFS时间为3.7(1.0~90.0)个月,中位OS时间为4.6(1.0~90.0)个月,两组生存曲线差异无统计学意义(OS及PFS P值分别为0.247和0.317)。auto-HSCT和allo-HSCT组的2年OS率分别为72%和50%,5年OS率分别为36%和25%。 结论: ALCL化疗反应率高,有不良预后因素的情况下化疗后序贯auto-HSCT为重要治疗措施,高危患者或可从allo-HSCT中获益。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lu N, Li XF, Dong YJ, et al. [Outcomes of 33 patients with anaplastic large cell lymphoma treated after hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32135627. doi:10.3760/cma.j.issn.0253-2727.2020.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。